 |
 | Vissza |
Gönczi Lóránt; Kürti Zsuzsanna; Rutka Mariann; Végh Zsuzsanna; Farkas Klaudia; Lovász Barbara Dorottya; Golovics Petra Anna; Gecse Krisztina Barbara; Szalay Balázs; Molnár Tamás; Lakatos Péter László:
Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
BMC GASTROENTEROLOGY, 17 (1).
Azonosító: 97.-Terjedelem: 7 p..
ISSN 1471-230X
(2017)
Bálint Anita; Rutka Mariann; Végh Zsuzsanna; Kürti Zsuzsanna; Gecse Krisztina Barbara; Lakatos László; Szepes Zoltán; Vincze Áron; Bor Renáta; Milassin Ágnes; Fábián Anna; Nagy Ferenc; Lakatos Péter László; Molnár Tamás; Farkas Klaudia:
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
EXPERT OPINION ON DRUG SAFETY, 16 (8).
pp. 885-890.
ISSN 1474-0338
(2017)
Gönczi Lóránt; Gecse Krisztina Barbara; Végh Zsuzsanna; Kürti Zsuzsanna; Rutka Mariann; Farkas Klaudia; Golovics Petra Anna; Lovász Barbara Dorottya; Banai János; Bene László; Gasztonyi Beáta; Kristóf Tünde; Lakatos László; Miheller Pál; Nagy Ferenc:
Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort.
INFLAMMATORY BOWEL DISEASES, 23 (11).
pp. 1908-1915.
ISSN 1078-0998
(2017)
Gönczi Lóránt; Végh Zsuzsanna; Golovics Petra Anna; Rutka Mariann; Gecse Krisztina Barbara; Bor Renáta; Farkas Klaudia; Szamosi Tamás; Bene László; Gasztonyi Beáta; Kristóf Tünde; Lakatos László; Miheller Pál; Palatka Károly; Papp Mária:
Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play a more important role?
JOURNAL OF CROHNS & COLITIS, 11 (6).
pp. 697-705.
ISSN 1873-9946
(2017)
Gecse Krisztina Barbara; Lovász Barbara Dorottya; Farkas Klaudia; Banai János; Bene László; Gasztonyi Beáta; Golovics Petra Anna; Csontos Ágnes Anna; Juhász Márk; Nagy Ferenc; Papp Mária; Szepes Zoltán; Vincze Áron; Szalay Balázs; Molnár Tamás; Lakatos Péter László:
Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective; multicentre; nationwide cohort.
JOURNAL OF CROHNS & COLITIS, 10 (2).
pp. 133-140.
ISSN 1873-9946
(2016)
Farkas Klaudia; Rutka Mariann; Golovics Petra Anna; Végh Zsuzsanna; Lovász Barbara Dorottya; Nyári Tibor András; Gecse Krisztina Barbara; Kolar Martin; Bortlik Martin; Duricovad Dana; Machkova Nadezda; Hruba Veronika; Bálint Anita; Nagy Ferenc; Bor Renáta; Milassin Ágnes; Szepes Zoltán; Palatka Károly; Lakatos Péter László; Lukasd Milan; Molnár Tamás:
Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis.
JOURNAL OF CROHNS & COLITIS, 10 (11).
pp. 1273-1278.
ISSN 1873-9946
(2016)
Kürti Zsuzsanna; Lovász Barbara Dorottya; Gecse Krisztina Barbara; Bálint Anita; Farkas Klaudia; Morocza-Szabó Ágnes; Gyurcsányi András; Kristóf Attila; Végh Zsuzsanna; Gönczi Lóránt; Kiss Lajos Sándor; Golovics Petra Anna; Lakatos László; Molnár Tamás; Lakatos Péter László:
Tuberculin skin test and Quantiferon in BCG vaccinated; immunosuppressed patients with moderate-to-severe inflammatory bowel disease.
Journal of Gastrointestinal and Liver Diseases, 24 (4).
pp. 467-472.
ISSN 1841-8724
(2015)
